close Icon

Research Articles

Explore our library of peer-reviewed publications below, with contributions from Burnet researchers.

See also: Research Reports + Policy Briefs

Form Loading Icon
Perceptions and experiences of the mistreatment of women during childbirth in health facilities in Guinea: a qualitative study with women and service providers.

Balde MD, Diallo BA, Bangoura A, Sall O, Soumah AM, Vogel JP, Bohren MA

Perceptions and experiences of the mistreatment of women during childbirth in health facilities in Guinea: a qualitative study with women and service providers.
Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.

Bonnet M, Bastard M, du Cros P, Khamraev A, Kimenye K, Khurkhumal S, Hayrapetyan A, Themba D, Telnov A, Sanchez-Padilla E, Hewison C, Varaine F

Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.
Barriers to new drug development in respiratory disease.

Brigden G, du Cros P, Wong S

Barriers to new drug development in respiratory disease.
Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia.

Goossens S, Peirs S, Van Loocke W, Wang J, Takawy M, Matthijssens F, Sonderegger SE, Haigh K, Nguyen T, Vandamme N, Costa M, Carmichael C, Van Nieuwerburgh F, Deforce D, Kleifeld O, Curtis DJ, Berx G, Van Vlierberghe P, Haigh JJ

Oncogenic ZEB2 activation drives sensitivity toward KDM1A inhibition in T-cell acute lymphoblastic leukemia.
Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia.

Alene KA, Viney K, McBryde ES, Tsegaye AT, Clements AC

Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia.
High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?

Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES

High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?